相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab
Ivan Adamec et al.
JOURNAL OF NEUROIMMUNOLOGY (2022)
Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials
Gavin Giovannoni et al.
EUROPEAN JOURNAL OF NEUROLOGY (2022)
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study
Sibyl Wray et al.
ADVANCES IN THERAPY (2022)
Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results
Ralf Gold et al.
MULTIPLE SCLEROSIS JOURNAL (2022)
S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal
Vasileios-Periklis Stamatellos et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)
Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis Results From Randomized Phase 2b Core and Extension Studies
Mark S. Freedman et al.
NEUROLOGY (2022)
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
Edward Fox et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Siponimod and Cognition in Secondary Progressive Multiple Sclerosis EXPAND Secondary Analyses
Ralph H. B. Benedict et al.
NEUROLOGY (2021)
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
Steve Simpson-Yap et al.
NEUROLOGY (2021)
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
H. Yesid Estupinan et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis
Reshmi Roy et al.
CNS DRUGS (2021)
Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera(R) (Dimethyl Fumarate)
Thomas W. Lategan et al.
CNS DRUGS (2021)
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study A Randomized Clinical Trial
Ludwig Kappos et al.
JAMA NEUROLOGY (2021)
Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab
Ramon E. Flores-Gonzalez et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)
Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment
I. Smets et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)
Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials
Sarah Harris et al.
EUROPEAN JOURNAL OF NEUROLOGY (2021)
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
Daniel S. Reich et al.
LANCET NEUROLOGY (2021)
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
Sokratis A. Apostolidis et al.
NATURE MEDICINE (2021)
Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study
Annette Wundes et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Anat Achiron et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)
Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study
Robert T. Naismith et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study
Robert T. Naismith et al.
CNS DRUGS (2020)
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
Anna He et al.
LANCET NEUROLOGY (2020)
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review
Huah Shin Ng et al.
EXPERT OPINION ON DRUG SAFETY (2020)
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
Jerry S. Wolinsky et al.
LANCET NEUROLOGY (2020)
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
Xavier Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Transcytosis route mediates rapid delivery of intact antibodies to draining lymph nodes
Laura Kahari et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study
Michael J. Palte et al.
ADVANCES IN THERAPY (2019)
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Simon Faissner et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
Jeffrey A. Cohen et al.
LANCET NEUROLOGY (2019)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
Giancarlo Comi et al.
LANCET NEUROLOGY (2019)
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
J. William L. Brown et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Progressive multiple sclerosis: latest therapeutic developments and future directions
Simon Faissner et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination
Abdelkrim Mannioui et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination
Abdelkrim Mannioui et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010
Simon Faissner et al.
CNS DRUGS (2018)
Metabolism and Disposition of Siponimod, a Novel Selective S1P1/S1P5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism
Ulrike Glaenzel et al.
DRUG METABOLISM AND DISPOSITION (2018)
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Ludwig Kappos et al.
LANCET (2018)
Substantial disease exacerbation in a patient with relapsing-remitting multiple sclerosis after withdrawal from siponimod
Tomasz Litwin et al.
NEUROLOGIA I NEUROCHIRURGIA POLSKA (2018)
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis The MIRROR study
Amit Bar-Or et al.
NEUROLOGY (2018)
Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab
Sherry Masoud et al.
RHEUMATOLOGY (2018)
Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study
Jonathan Q. Tran et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2018)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity
F. L. Scott et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
Antonietta Gentile et al.
JOURNAL OF NEUROINFLAMMATION (2016)
The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures
Catherine O'Sullivan et al.
JOURNAL OF NEUROINFLAMMATION (2016)
Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment
Simon Faissner et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial
Tomas Olsson et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study
Per S. Sorensen et al.
NEUROLOGY (2014)
Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics
Regina Kurrasch et al.
JOURNAL OF RHEUMATOLOGY (2013)
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
Krzysztof Selmaj et al.
LANCET NEUROLOGY (2013)
Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator
Shifeng Pan et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate
P. Gergely et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
Andrew W. Pawluczkowycz et al.
JOURNAL OF IMMUNOLOGY (2009)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate
MG Sanna et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
分享论文
